ClinicalTrials.gg
RecruitingNCT07214987Updated Oct 19, 2026

PDT For Induction Therapy For Head And Neck Cancer

A Phase 2 interventional study of Toripalimab-tpzi and Cisplatin in Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma and Head and Neck Cancer, sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Carcinoma, Squamous CellReclassifiedWhy we changed it
Registry
Carcinoma, Squamous Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's title name Squamous Cell Carcinoma of Head and Neck, a narrower term within Carcinoma, Squamous Cell.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 19, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck — 19 open to participants now, 31 under way, 5 of them phase 3. Cisplatin · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
82nd of 107
26 · median 47
Started
2026
with 6 others
Phase 2
70 of 115
18 open now
Primary completion
2027-12
later than 15 of 30 live
Registered
108th of 115
by date

Among the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, this one is the 82nd largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2026, is one of 70 in phase 2, reaches primary completion later than 15 of the 30 other live ones, and was the 108th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

19 of the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

Read the detailed description

This is a single arm phase II study to assess treatment-related adverse events (TRAEs) and efficacy of PDT. The study employs a Simon two-stage design. After 12 evaluable participants start treatment with at least 2 participants experiencing no grade 3 or higher TRAEs during induction therapy, then enrollment will continue to the target number of participants of 26. Participants will receive treatment for three cycles or until disease progression, they experience unacceptable side effects, their condition changes rendering them unacceptable for further treatment, or they withdraw from the study. Participants will be followed for two years from registration. Coherus Biosciences, Inc. is supporting this research study by providing the study drug, toripalimab, and funding for research activities. The U.S. FDA has not approved toripalimab for CPS-positive locally advanced HNSCC but has approved it for other forms of head and neck cancer. Toripalimab is a lab-made antibody that works by allowed the immune system to attack cancer cells more effectively. Toripalimab is currently sold as LOQTORZI and is used with cisplatin and gemcitabine to treat nasopharyngeal carcinoma. The U.S. FDA has approved cisplatin and docetaxel as a treatment option for multiple types of cancers, including head and neck small cell carcinoma. Cisplatin is a chemotherapy agent that works by binding to cancer cells and initiating cell death. Docetaxel is a chemotherapy agent made from a compound found in the European yew tree. Docetaxel works by stabilizing tiny structures within cancer cells, prevent cell growth and, ultimately leading to cell death. The combination of toripalimab with cisplatin and docetaxel for induction therapy is investigational.

03

Conditions studied

  • Squamous Cell Carcinoma
  • Head and Neck Cancer Squamous Cell Carcinoma
  • Head and Neck Cancer

Keywords

  • Head and Neck Squamous Cell Carcinoma
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's planned enrollment of 26 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma, Squamous Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a new diagnosis of or cytologically confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, sinonasal cavities or unknown primary HNSCC.
  • Participants with HPV-independent SCC or HNSCC or other head and neck subsites must have stage III or non- stage IV at the time of diagnosis. Participants with HPV-associated oropharynx SCC must have stage II or stage III disease.
  • Participants must be determined by the investigator to be candidates for induction systemic therapy due to reasons such as the extent of primary tumor at the time of diagnosis, rate of progression, symptom burden or potential benefit of cytoreduction prior to definitive local therapy.
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of toripalimab in combination with cisplatin and docetaxel in participants \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
  • performance status ≤ 1
  • of greater than 12 weeks.
  • Participants must meet the following organ and marrow function as defined below:

≥8.0 g/dL ≥1500/mcL ≥100,000/mcL total ≤ 2 institutional (ULN) (SGOT)/ALT(SGPT) ≤ 2 × institutional ULN creatinine ≤ 2 x institutional ULN OR (GFR) ≥ 45 mL/min/1.73 m2

  • Participants with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Because immunotherapy agents as well as cisplatin and docetaxel are known to be teratogenic, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of toripalimab administration.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of EBV-associated nasopharynx squamous cell carcinoma
  • Strong clinical suspicion or histologic confirmation of cutaneous squamous cell carcinoma
  • Histology other than squamous cell carcinoma.
  • Proven distant (below the clavicle) by clinical or radiographic measures.
  • Prior radiotherapy to the head and/or neck that excludes the patient from receiving curative-intent radiation to involved areas.
  • Pre-existing peripheral neuropathy grade 2 or higher
  • Participants who are receiving any other agents for this condition.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to toripalimab, cisplatin or docetaxel.
  • An condition requiring treatment with systemic within the past 30 days. Long-term steroid replacement for patients with adrenal insufficiency is allowed.
  • Presence of a second that is considered active by the investigator. A second malignancy should be considered active if any one of the following are present: Administration of antineoplastic therapy for the second malignancy in the previous 6 months; radiographic changes in the prior 6 months that are attributed to the second malignancy; Concern by the investigator that the second malignancy may require antineoplastic treatment during the patient's treatment for their head and neck cancer or in the next 6 months, whichever timeframe is expected to be longer
  • Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
  • Pregnant women are excluded from this study because toripalimab, cisplatin and docetaxel have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with toripalimab, cisplatin and docetaxel, breastfeeding should be discontinued if the mother is treated with toripalimab. These potential risks may also apply to other agents used in this study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    PDT (cisplatin + docetaxel + toripalimab) induction therapy

    Toripalimab, cisplatin, and docetaxel will be given once every 21 days, +/- a window of 5 days, by intravenous infusion. On day 1 of each cycle, the pre-determined dose of toripalimab will be administered over about 60 minutes. The pre-determined dose of docetaxel will then be administered over about 1 hour. After docetaxel, the pre-determined dose of cisplatin will be administered over about 1-3 hours. This will continue for up to 3 cycles. Participants may be pre-medicated with drugs to reduce the chance of having a sensitivity reaction to the study treatment. The decision to pursue definitive chemoradiotherapy should be made by a multidisciplinary team specializing in treating head and neck cancers. For patients receiving chemoradiotherapy, the recommended concurrent chemotherapy regimen used with radiotherapy is weekly cisplatin.

    Drug: Toripalimab-tpzi · Drug: Cisplatin · Drug: Docetaxel

Interventions

  • DrugToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab-tpzi is a humanized IgG4 monoclonal antibody specific against human PD-1.

    Also known as: JS001, TAB001, CHS-007, LOQTORZI

  • Cisplatin is an injectable chemotherapy agent classified as a platinum-based alkylating agent.

  • Docetaxel is a taxane chemotherapy agent.

07

What researchers measure

Primary outcomes

  1. Proportion Grade 3-5 TRAE-free during induction therapy

    Assessed using NCI Common Terminology for Adverse Event (CTCAE) version 5.0. The rate of patients with grade 3+ TRAEs-free during induction therapy will be summarized as a proportion with a corresponding exact 95% confidence interval (CI) (if the trial closes to accrual after the first stage), or a proportion with a corresponding 95% two-stage confidence interval (CI) if the trial closes to accrual after the second stage.

    Time frame: Day 1 of Cycle 1 (each cycle is 21 days) to Day 10 of Cycle 3 (end of induction therapy).

Secondary outcomes

  1. Overall Response Rate (ORR) after PDT induction therapy

    The overall response rate (ORR) will be summarized as a proportion with a corresponding exact 95% two-stage confidence interval (CI).

    Time frame: Day 1 of Cycle 1 (each cycle is 21 days) to day 1 of cycle 3.

  2. Overall Response Rate (ORR) after curative-intent therapy

    The overall response rate (ORR) will be summarized as a proportion with a corresponding exact 95% two-stage confidence interval (CI).

    Time frame: Day 1 of Cycle 3 (each cycle is 21 days) to day of 3-month follow-up visit.

  3. Event-free Survival

    The Kaplan-Meier method will be used to estimate time-to-event endpoints with corresponding 95% confidence intervals (CIs) for the median or time-specific event time.

    Time frame: Day 1 of Cycle 1 (each cycle is 21 days) to date of death or for up to 2 years from study registration (whichever comes first).

  4. Overall Survival

    Overall survival is the time from start of treatment to death due to any cause. The Kaplan-Meier method will be used to estimate time-to-event endpoints with corresponding 95% confidence intervals (CIs) for the median or time-specific event time.

    Time frame: Day 1 of Cycle 1 (each cycle is 21 days) to date of death or for up to 2 years from study registration (whichever comes first).

  5. Participant's Quality of Life

    Patient-Reported Outcomes Measurement Information System Global 10 (PROMIS-10) Physical Health T-score and Global Mental Health T-score will be summarized descriptively via PROMIS-10 scores. The minimum score is 16 and the maximum is 68. A higher score is associated with better outcomes.

    Time frame: Baseline until to 2 years from study registration.

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Thomas Roberts, MD, MBA at 617-726-5130. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication.

Access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 21 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 9, 2025
StartActual
Mar 9, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Sep 1, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion removed; 1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedCPS ≥ 1%
Exclusion criteria
  • ChangedBefore Prior radiotherapy to the head and/or neck with the exception of radiation for cutaneous malignancies involving radiation fields that do not overlap with areas of current disease involvement.Now Prior radiotherapy to the head and/or neck that excludes the patient from receiving curative-intent radiation to involved areas.
  • RemovedAny second malignancy that required antineoplastic therapy in the previous 6 months.
  • AddedPresence of a second malignancy that is considered active by the investigator. A second malignancy should be considered active if any one of the following are present: Administration of antineoplastic therapy for the second malignancy in the previous 6 months; Clinically significant radiographic changes in the prior 6 months that are attributed to the second malignancy; Concern by the investigator that the second malignancy may require antineoplastic treatment during the patient's treatment for their head and neck cancer or in the next 6 months, whichever timeframe is expected to be longer
Oct 19, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedProportion Grade 3-5 TRAE-free during curative-intent treatmentTime frame: Day 1 of Cycle 1 (each cycle is 21 days) through the completion of 7 weeks of definitive chemoRT or 30 days after surgery for patients who undergo surgery and are deemed by the treating team to not require additional post-operative therapy.
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedCPS ≥ 1%
    Exclusion criteria
    • ChangedBefore Prior radiotherapy to the head and/or neck with the exception of radiation for cutaneous malignancies involving radiation fields that do not overlap with areas of current disease involvement.Now Prior radiotherapy to the head and/or neck that excludes the patient from receiving curative-intent radiation to involved areas.
    • RemovedAny second malignancy that required antineoplastic therapy in the previous 6 months.
    • AddedPresence of a second malignancy that is considered active by the investigator. A second malignancy should be considered active if any one of the following are present: Administration of antineoplastic therapy for the second malignancy in the previous 6 months; Clinically significant radiographic changes in the prior 6 months that are attributed to the second malignancy; Concern by the investigator that the second malignancy may require antineoplastic treatment during the patient's treatment for their head and neck cancer or in the next 6 months, whichever timeframe is expected to be longer
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedProportion Grade 3-5 TRAE-free during curative-intent treatmentTime frame: Day 1 of Cycle 1 (each cycle is 21 days) through the completion of 7 weeks of definitive chemoRT or 30 days after surgery for patients who undergo surgery and are deemed by the treating team to not require additional post-operative therapy.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07214987
Collaborators
Coherus Oncology, Inc.
Responsible party
Thomas J. Roberts, MD (Principle Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Oct 9, 2025
Start date
Mar 9, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Thomas Roberts, MD, MBA
Contact
thomas.roberts@mgh.harvard.edu
617-726-5130
Thomas Roberts, MD, MBA
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Docetaxel

Start the discussion